{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:01:26Z","timestamp":1794344486140,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CPII17\/00015"],"award-info":[{"award-number":["CPII17\/00015"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00796"],"award-info":[{"award-number":["PI18\/00796"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/12\/00317"],"award-info":[{"award-number":["CB16\/12\/00317"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/12\/00273"],"award-info":[{"award-number":["CB16\/12\/00273"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["ICI20\/00057"],"award-info":[{"award-number":["ICI20\/00057"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cient\u00edficas","doi-asserted-by":"publisher","award":["PID2020-115605RB-I00"],"award-info":[{"award-number":["PID2020-115605RB-I00"]}],"id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["CSI146P20"],"award-info":[{"award-number":["CSI146P20"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALMOM"},{"name":"ACMUMA"},{"name":"UCCTA"},{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["I00\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["I00\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003339","name":"Consejo Superior de Investigaciones Cientificas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Advanced colorectal cancer (CRC) is difficult to treat. For that reason, the development of novel therapeutics is necessary. Here we describe a potentially actionable plasma membrane target, the amino acid transporter protein subunit CD98hc.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Western blot and immunohistochemical analyses of CD98hc protein expression were carried out on paired normal and tumoral tissues from patients with CRC. Immunofluorescence and western studies were used to characterize the action of a DM1-based CD98hc-directed antibody\u2013drug conjugate (ADC). MTT and Annexin V studies were performed to evaluate the effect of the anti-CD98hc-ADC on cell proliferation and apoptosis. CRISPR\/Cas9 and shRNA were used to explore the specificity of the ADC. In vitro analyses of the antitumoral activity of the anti-CD98hc-ADC on 3D patient-derived normal as well as tumoral organoids were also carried out. Xenografted CRC cells and a PDX were used to analyze the antitumoral properties of the anti-CD98hc-ADC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Genomic as well proteomic analyses of paired normal and tumoral samples showed that CD98hc expression was significantly higher in tumoral tissues as compared to levels of CD98hc present in the normal colonic tissue. In human CRC cell lines, an ADC that recognized the CD98hc ectodomain, reached the lysosomes and exerted potent antitumoral activity. The specificity of the CD98hc-directed ADC was demonstrated using CRC cells in which CD98hc was decreased by shRNA or deleted using CRISPR\/Cas9. Studies in patient-derived organoids verified the antitumoral action of the anti-CD98hc-ADC, which largely spared normal tissue-derived colon organoids. In vivo studies using xenografted CRC cells or patient-derived xenografts confirmed the antitumoral activity of the anti-CD98hc-ADC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The studies herewith reported indicate that CD98hc may represent a novel ADC target that, upon well-designed clinical trials, could be used to increase the therapeutic armamentarium against CRC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-023-02784-0","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T06:01:41Z","timestamp":1691560901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["An amino acid transporter subunit as an antibody\u2013drug conjugate target in colorectal cancer"],"prefix":"10.1186","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4773-053X","authenticated-orcid":false,"given":"Juan Carlos","family":"Montero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"del Carmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Sayagu\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barb\u00e1chano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asunci\u00f3n","family":"Fern\u00e1ndez-Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanasio","family":"Pandiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"2784_CR1","first-page":"10 101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:10 101174.","journal-title":"Transl Oncol"},{"key":"2784_CR2","doi-asserted-by":"crossref","first-page":"175883592110727","DOI":"10.1177\/17588359211072703","volume":"14","author":"JE Riedesser","year":"2022","unstructured":"Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol. 2022;14:17588359211072704.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"2784_CR3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.soc.2021.11.006","volume":"31","author":"S Sakata","year":"2022","unstructured":"Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31(2):255\u201364.","journal-title":"Surg Oncol Clin N Am"},{"issue":"18","key":"2784_CR4","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.3390\/cancers13184631","volume":"13","author":"L Gandullo-S\u00e1nchez","year":"2021","unstructured":"Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A. Generation of antibody-drug conjugate resistant Models. Cancers (Basel). 2021;13(18):4631.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2784_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021;14(1):20.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2784_CR6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-0442","volume":"17","author":"RM Sharkey","year":"2018","unstructured":"Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, et al. Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody-Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). Mol Cancer Ther. 2018;17(1):196\u2013203.","journal-title":"Mol Cancer Ther"},{"issue":"29","key":"2784_CR7","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, Simpson PS, et al. Phase I\/II Trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017;35(29):3338\u201346.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2784_CR8","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1158\/1535-7163.MCT-19-0452","volume":"18","author":"S Koganemaru","year":"2019","unstructured":"Koganemaru S, Kuboki Y, Koga Y, Kojima T, Yamauchi M, Maeda N, et al. U3\u20131402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Mol Cancer Ther. 2019;18(11):2043\u201350.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2784_CR9","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cancers13051047","volume":"13","author":"K Yonesaka","year":"2021","unstructured":"Yonesaka K. HER2-\/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers (Basel). 2021;13(5):1047.","journal-title":"Cancers (Basel)"},{"key":"2784_CR10","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2020.38.15_suppl.4000","volume":"38","author":"S Siena","year":"2020","unstructured":"Siena S, Bartolomeo MD, Raghav KPS, Masuishi T, Loupakis F, Kawakami H, et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01. J Clin Oncol. 2020;38:4000.","journal-title":"J Clin Oncol."},{"issue":"3","key":"2784_CR11","doi-asserted-by":"crossref","first-page":"100102","DOI":"10.1016\/j.esmoop.2021.100102","volume":"6","author":"F Schettini","year":"2021","unstructured":"Schettini F, Barbao P, Bras\u00f3-Maristany F, Galv\u00e1n P, Mart\u00ednez D, Par\u00e9 L, et al. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open. 2021;6(3):100102.","journal-title":"ESMO Open"},{"issue":"12","key":"2784_CR12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","volume":"2","author":"Z Hu","year":"2021","unstructured":"Hu Z, Yuan J, Long M, Jiang J, Zhang Y, Zhang T, et al. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat Cancer. 2021;2(12):1406\u201322.","journal-title":"Nat Cancer"},{"issue":"8","key":"2784_CR13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","volume":"11","author":"MA Nix","year":"2021","unstructured":"Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, et al. Surface Proteomics Reveals CD72 as a Target for. Cancer Discov. 2021;11(8):2032\u201349.","journal-title":"Cancer Discov"},{"issue":"1","key":"2784_CR14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13046-022-02330-4","volume":"41","author":"JC Montero","year":"2022","unstructured":"Montero JC, Calvo-Jim\u00e9nez E, Del Carmen S, Abad M, Oca\u00f1a A, Pandiella A. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. J Exp Clin Cancer Res. 2022;41(1):106.","journal-title":"J Exp Clin Cancer Res"},{"issue":"632","key":"2784_CR15","doi-asserted-by":"crossref","first-page":"eaax7706","DOI":"10.1126\/scitranslmed.aax7706","volume":"14","author":"K Hasegawa","year":"2022","unstructured":"Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, et al. Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Sci Transl Med. 2022;14(632):eaax7706.","journal-title":"Sci Transl Med"},{"issue":"Pt 6","key":"2784_CR16","first-page":"1373","volume":"125","author":"JM Cantor","year":"2012","unstructured":"Cantor JM, Ginsberg MH. CD98 at the crossroads of adaptive immunity and cancer. J Cell Sci. 2012;125(Pt 6):1373\u201382.","journal-title":"J Cell Sci"},{"issue":"5","key":"2784_CR17","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1074\/jbc.274.5.3009","volume":"274","author":"E Nakamura","year":"1999","unstructured":"Nakamura E, Sato M, Yang H, Miyagawa F, Harasaki M, Tomita K, et al. 4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer. J Biol Chem. 1999;274(5):3009\u201316.","journal-title":"J Biol Chem"},{"issue":"12","key":"2784_CR18","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1111\/j.1349-7006.2008.00969.x","volume":"99","author":"K Kaira","year":"2008","unstructured":"Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 2008;99(12):2380\u20136.","journal-title":"Cancer Sci"},{"issue":"4","key":"2784_CR19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.ejca.2013.11.010","volume":"50","author":"MM Rietbergen","year":"2014","unstructured":"Rietbergen MM, de MartensKemp SR, Bloemena E, Witte BI, Brink A, de BaatenburgJong RJ, et al. Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer. 2014;50(4):765\u201373.","journal-title":"Eur J Cancer"},{"issue":"4","key":"2784_CR20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3892\/or.2010.861","volume":"24","author":"K Kaira","year":"2010","unstructured":"Kaira K, Takahashi T, Abe M, Akamatsu H, Nakagawa K, Ohde Y, et al. CD98 expression is associated with the grade of malignancy in thymic epithelial tumors. Oncol Rep. 2010;24(4):861\u20137.","journal-title":"Oncol Rep"},{"issue":"6","key":"2784_CR21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1499-3872(14)60278-2","volume":"13","author":"K Kaira","year":"2014","unstructured":"Kaira K, Sunose Y, Oriuchi N, Kanai Y, Takeyoshi I. CD98 is a promising prognostic biomarker in biliary tract cancer. Hepatobiliary Pancreat Dis Int. 2014;13(6):654\u20137.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"2784_CR22","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2362.2009.02096.x","volume":"39","author":"GW Prager","year":"2009","unstructured":"Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, et al. CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest. 2009;39(4):304\u201310.","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"2784_CR23","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/bjc.2014.178","volume":"110","author":"M Toyoda","year":"2014","unstructured":"Toyoda M, Kaira K, Ohshima Y, Ishioka NS, Shino M, Sakakura K, et al. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer. Br J Cancer. 2014;110(10):2506\u201313.","journal-title":"Br J Cancer"},{"issue":"4","key":"2784_CR24","first-page":"931","volume":"26","author":"K Kaira","year":"2011","unstructured":"Kaira K, Ohde Y, Endo M, Nakagawa K, Okumura T, Takahashi T, et al. Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncol Rep. 2011;26(4):931\u20137.","journal-title":"Oncol Rep"},{"issue":"4","key":"2784_CR25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jso.24160","volume":"113","author":"H Honjo","year":"2016","unstructured":"Honjo H, Kaira K, Miyazaki T, Yokobori T, Kanai Y, Nagamori S, et al. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma. J Surg Oncol. 2016;113(4):381\u20139.","journal-title":"J Surg Oncol"},{"issue":"2","key":"2784_CR26","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1349-7006.2011.02151.x","volume":"103","author":"M Furuya","year":"2012","unstructured":"Furuya M, Horiguchi J, Nakajima H, Kanai Y, Oyama T. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103(2):382\u20139.","journal-title":"Cancer Sci"},{"issue":"Suppl 1","key":"2784_CR27","first-page":"E52","volume":"54","author":"X Guo","year":"2015","unstructured":"Guo X, Li H, Fei F, Liu B, Li X, Yang H, et al. Genetic variations in SLC3A2\/CD98 gene as prognosis predictors in non-small cell lung cancer. Mol Carcinog. 2015;54(Suppl 1):E52\u201360.","journal-title":"Mol Carcinog"},{"issue":"5","key":"2784_CR28","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cam4.272","volume":"3","author":"N Yanagisawa","year":"2014","unstructured":"Yanagisawa N, Hana K, Nakada N, Ichinoe M, Koizumi W, Endou H, et al. High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas. Cancer Med. 2014;3(5):1246\u201355.","journal-title":"Cancer Med"},{"issue":"3","key":"2784_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/pcmr.12464","volume":"29","author":"N Theodosakis","year":"2016","unstructured":"Theodosakis N, Micevic G, Sharma R, Baras AS, Lazova R, Bosenberg MW, et al. Integrative discovery of CD98 as a melanoma biomarker. Pigment Cell Melanoma Res. 2016;29(3):385\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"7","key":"2784_CR30","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.7150\/jca.70500","volume":"13","author":"D Bianconi","year":"2022","unstructured":"Bianconi D, Fabian E, Herac M, Kieler M, Thaler J, Prager G, et al. Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. J Cancer. 2022;13(7):2271\u201380.","journal-title":"J Cancer"},{"issue":"12","key":"2784_CR31","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1136\/gutjnl-2021-325137","volume":"71","author":"S Tian","year":"2022","unstructured":"Tian S, Chu Y, Hu J, Ding X, Liu Z, Fu D, et al. Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. Gut. 2022;71(12):2489\u2013501.","journal-title":"Gut"},{"issue":"1","key":"2784_CR32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00018-022-04668-6","volume":"80","author":"AR Rebelo","year":"2023","unstructured":"Rebelo AR, Homem CCF. dMyc-dependent upregulation of CD98 amino acid transporters is required for Drosophila brain tumor growth. Cell Mol Life Sci. 2023;80(1):30.","journal-title":"Cell Mol Life Sci"},{"key":"2784_CR33","doi-asserted-by":"crossref","first-page":"153730","DOI":"10.1016\/j.prp.2021.153730","volume":"229","author":"D Lee","year":"2022","unstructured":"Lee D, Kim HS, Kim HU, Song HJ, Lee C, Kim DY, et al. Expression profile of CD98 heavy chain and L-type amino acid transporter 1 and its prognostic significance in colorectal cancer. Pathol Res Pract. 2022;229:153730.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"2784_CR34","first-page":"5418","volume":"10","author":"Y Ye","year":"2017","unstructured":"Ye Y, Wang M, Wang B, Li Y, Yang X-M, Chen Z-N. CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients. Int J Clin Exp Pathol. 2017;10(5):5418\u201329.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"2784_CR35","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1021\/acsnano.7b08499","volume":"12","author":"B Xiao","year":"2018","unstructured":"Xiao B, Viennois E, Chen Q, Wang L, Han MK, Zhang Y, et al. Silencing of intestinal glycoprotein cd98 by orally targeted nanoparticles enhances chemosensitization of colon cancer. ACS Nano. 2018;12(6):5253\u201365.","journal-title":"ACS Nano"},{"issue":"21","key":"2784_CR36","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1038\/onc.2015.337","volume":"35","author":"S Seoane","year":"2016","unstructured":"Seoane S, Montero JC, Ocana A, Pandiella A. Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. Oncogene. 2016;35(21):2756\u201365.","journal-title":"Oncogene"},{"issue":"4","key":"2784_CR37","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00018-020-03617-5","volume":"78","author":"JC Montero","year":"2021","unstructured":"Montero JC, Pandiella A. PDCD4 limits prooncogenic neuregulin-ErbB signaling. Cell Mol Life Sci. 2021;78(4):1799\u2013815.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"2784_CR38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ijc.20793","volume":"114","author":"A Esparis-Ogando","year":"2005","unstructured":"Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutierrez N, Blade J, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005;114(4):665\u20137.","journal-title":"Int J Cancer"},{"issue":"Pt 2","key":"2784_CR39","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bj3630211","volume":"363","author":"JC Montero","year":"2002","unstructured":"Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochem J. 2002;363(Pt 2):211\u201321.","journal-title":"Biochem J"},{"issue":"1","key":"2784_CR40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/febs.14998","volume":"287","author":"A Fern\u00e1ndez-Barral","year":"2020","unstructured":"Fern\u00e1ndez-Barral A, Costales-Carrera A, Buira SP, Jung P, Ferrer-Mayorga G, Larriba MJ, et al. Vitamin D differentially regulates colon stem cells in patient-derived normal and tumor organoids. FEBS J. 2020;287(1):53\u201372.","journal-title":"FEBS J"},{"issue":"4","key":"2784_CR41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","volume":"161","author":"M van de Wetering","year":"2015","unstructured":"van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161(4):933\u201345.","journal-title":"Cell"},{"issue":"1","key":"2784_CR42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/MCB.22.1.270-285.2002","volume":"22","author":"A Espar\u00eds-Ogando","year":"2002","unstructured":"Espar\u00eds-Ogando A, D\u00edaz-Rodr\u00edguez E, Montero JC, Yuste L, Crespo P, Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol. 2002;22(1):270\u201385.","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2784_CR43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/md17110648","volume":"17","author":"A Costales-Carrera","year":"2019","unstructured":"Costales-Carrera A, Fern\u00e1ndez-Barral A, Bustamante-Madrid P, Guerra L, Cantero R, Barb\u00e1chano A, et al. Plocabulin displays strong cytotoxic activity in a personalized colon cancer patient-derived 3D organoid assay. Mar Drugs. 2019;17(11):648.","journal-title":"Mar Drugs"},{"issue":"1","key":"2784_CR44","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1038\/s41598-020-61688-7","volume":"10","author":"S Del Carmen","year":"2020","unstructured":"Del Carmen S, Corchete LA, Gervas R, Rodriguez A, Garcia M, \u00c1lcazar JA, et al. Prognostic implications of EGFR protein expression in sporadic colorectal tumors: Correlation with copy number status, mRNA levels and miRNA regulation. Sci Rep. 2020;10(1):4662.","journal-title":"Sci Rep"},{"issue":"5","key":"2784_CR45","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/ijms22052622","volume":"22","author":"\u00c1 Bartha","year":"2021","unstructured":"Bartha \u00c1, Gy\u0151rffy B. TNMplot.com: a web tool for the comparison of gene expression in normal, tumor and metastatic tissues. Int J Mol Sci. 2021;22(5):2622.","journal-title":"Int J Mol Sci"},{"issue":"W1","key":"2784_CR46","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556\u201360.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2784_CR47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","volume":"81","author":"RA Weinberg","year":"1995","unstructured":"Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81(3):323\u201330.","journal-title":"Cell"},{"issue":"9","key":"2784_CR48","first-page":"2003","volume":"56","author":"PP Claudio","year":"1996","unstructured":"Claudio PP, De Luca A, Howard CM, Baldi A, Firpo EJ, Koff A, et al. Functional analysis of pRb2\/p130 interaction with cyclins. Cancer Res. 1996;56(9):2003\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"2784_CR49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"M Barok","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"2784_CR50","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2868","volume":"13","author":"M Barok","year":"2011","unstructured":"Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 2011;13(2):R46.","journal-title":"Breast Cancer Res"},{"issue":"15","key":"2784_CR51","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/0008-5472.CAN-15-3376","volume":"76","author":"Y Cormerais","year":"2016","unstructured":"Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutt\u00e9 E, et al. Genetic Disruption of the Multifunctional CD98\/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth. Cancer Res. 2016;76(15):4481\u201392.","journal-title":"Cancer Res"},{"issue":"7","key":"2784_CR52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8(7):547\u201366.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2784_CR53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"S Garc\u00eda-Alonso","year":"2020","unstructured":"Garc\u00eda-Alonso S, Oca\u00f1a A, Pandiella A. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. Trends Cancer. 2020;6(2):130\u201346.","journal-title":"Trends Cancer"},{"issue":"3","key":"2784_CR54","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ijc.29415","volume":"137","author":"GM Hayes","year":"2015","unstructured":"Hayes GM, Chinn L, Cantor JM, Cairns B, Levashova Z, Tran H, et al. Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015;137(3):710\u201320.","journal-title":"Int J Cancer"},{"issue":"7","key":"2784_CR55","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/cancers14071677","volume":"14","author":"AS K\u00f6seer","year":"2022","unstructured":"K\u00f6seer AS, Loureiro LR, Jureczek J, Mitwasi N, Gonz\u00e1lez Soto KE, Aepler J, et al. Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2022;14(7):1677.","journal-title":"Cancers (Basel)"},{"key":"2784_CR56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2022.03.157","volume":"608","author":"Y Chen","year":"2022","unstructured":"Chen Y, Cao A, Li Q, Quan J. Identification of DNA aptamers that specifically targets EBV. Biochem Biophys Res Commun. 2022;608:135\u201341.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"2784_CR57","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/cas.13021","volume":"107","author":"Y Ohshima","year":"2016","unstructured":"Ohshima Y, Kaira K, Yamaguchi A, Oriuchi N, Tominaga H, Nagamori S, et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci. 2016;107(10):1499\u2013505.","journal-title":"Cancer Sci"},{"issue":"4","key":"2784_CR58","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1111\/jcmm.14176","volume":"23","author":"Y Cormerais","year":"2019","unstructured":"Cormerais Y, Pagnuzzi-Boncompagni M, Schr\u00f6tter S, Giuliano S, Tambutt\u00e9 E, Endou H, et al. Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma. J Cell Mol Med. 2019;23(4):2711\u20138.","journal-title":"J Cell Mol Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-023-02784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-023-02784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T23:33:50Z","timestamp":1700350430000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-023-02784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1186\/s13046-023-02784-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"10 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Funding section was updated. \u2018Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.\u2019 has been deleted.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The samples of patients with CRC used in this study were from surgical resection and were obtained following the Declaration of Helsinki on ethical principles for medical research involving human subjects. Written informed consent for research use of tissue samples was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}